Potential clinical implications of BRAF mutations in histiocytic proliferations

Oncotarget

Volumn 5, Issue 12, 2014, Pages 4060-4070

  Bubolz, Anna Maria ^a   Weissinger, Stephanie E ^a   Stenzinger, Albrecht ^b   Arndt, Annette ^c   Steinestel, Konrad ^c,d   Brüderlein, Silke ^a   Cario, Holger ^a   Lubatschofski, Anneli ^a   Welke, Claudia ^e   Anagnostopoulos, Ioannis ^f   Barth, Thomas F E ^a   Beer, Ambros J ^a   Möller, Peter ^a   Gottstein, Martin ^a   Viardot, Andreas ^a   Lennerz, Jochen K ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c BUNDESWEHRKRANKENHAUS ULM   (Germany)

^d Bundeswehr Institute of Radiobiology   (Germany)

^e UNIVERSITY HOSPITAL ULM   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Biomarker; Erdheim chester; Langerhans; V600E

Indexed keywords

B RAF KINASE; CLADRIBINE; FLUORODEOXYGLUCOSE; GLUCOCORTICOID; VEMURAFENIB; VINBLASTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAF GENE; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL PROLIFERATION; CHILD; DENDRITIC CELL SARCOMA; DRUG EFFICACY; FEMALE; GENE MUTATION; GENOTYPE; GRANULAR CELL TUMOR; HISTIOCYTE; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; INFANT; JUVENILE XANTHOGRANULOMA; LANGERHANS CELL; LANGERHANS CELL HISTIOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MUTANT; MUTATION RATE; MUTATIONAL ANALYSIS; NEWBORN; OBSERVATIONAL STUDY; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; REFRACTORY PERIOD; RETROSPECTIVE STUDY; SALVAGE THERAPY; SINUS HISTIOCYTOSIS; TREATMENT DURATION; ULTRASTRUCTURE; WILD TYPE; GENETICS; IMMUNOLOGY; MUTATION; PATHOLOGY; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; FEMALE; GENOTYPE; HISTIOCYTES; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; YOUNG ADULT;

EID: 84905124784     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2061     Document Type: Article

References (58)

1. Pileri SA, Grogan TM, Harris NL, Banks P, Campo E, Chan JK, Favera RD, Delsol G, De Wolf-Peeters C, Falini B, Gascoyne RD, Gaulard P, Gatter KC, et al. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology. 2002; 41(1):1-29.
2. Isaacson P, Jones DB, Sworn MJ and Wright DH. Malignant histiocytosis of the intestine: report of three cases with immunological and cytochemical analysis. J Clin Pathol. 1982; 35(5):510-516.
3. Orfanos CE and Lammer D. [Reticulohistiocytic tumors of the skin. New concepts]. Hautarzt. 1980; 31(6):297-307.
4. Nezelof C and Basset F. Langerhans cell histiocytosis research. Past, present, and future. Hematol Oncol Clin North Am. 1998; 12(2):385-406.
5. Chu T, D'Angio GJ, Favara BE, Ladisch S, Nesbit M and Pritchard J. Histiocytosis syndromes in children. Lancet. 1987; 2(8549):41-42.
6. Howarth DM, Gilchrist GS, Mullan BP, Wiseman GA, Edmonson JH and Schomberg PJ. Langerhans cell histiocytosis: diagnosis, natural history, management, and outcome. Cancer. 1999; 85(10):2278-2290.
7. Willis B, Ablin A, Weinberg V, Zoger S, Wara WM and Matthay KK. Disease course and late sequelae of Langerhans' cell histiocytosis: 25-year experience at the University of California, San Francisco. J Clin Oncol. 1996; 14(7):2073-2082.
8. Janku F, Amin HM, Yang D, Garrido-Laguna I, Trent JC and Kurzrock R. Response of histiocytoses to imatinib mesylate: fire to ashes. J Clin Oncol. 2010; 28(31):e633-636.
9. Montella L, Insabato L and Palmieri G. Imatinib mesylate for cerebral Langerhans'-cell histiocytosis. N Engl J Med. 2004; 351(10):1034-1035.
10. Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML, Kuo FC, Ligon AH, Stevenson KE, Kehoe SM, Garraway LA, Hahn WC, Meyerson M, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010; 116(11):1919-1923.
11. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul. 2006; 46:249-279.
12. Wong KK. Recent developments in anti-cancer agents targeting the Ras/Raf/MEK/ERK pathway. Recent Pat Anticancer Drug Discov. 2009; 4(1):28-35.
13. Hoeflich KP, Herter S, Tien J, Wong L, Berry L, Chan J, O'Brien C, Modrusan Z, Seshagiri S, Lackner M, Stern H, Choo E, Murray L, et al. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res. 2009; 69(7):3042-3051.
14. Heakal Y, Kester M and Savage S. Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma. Ann Pharmacother. 2011; 45(11):1399-1405.
15. Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Espinosa E, Garbe C, Sileni VC, Gogas H, Miller WH, Jr., Mandala M, Hospers GA, et al. Vemurafenib in patients with BRAF mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 2014.
16. Berres ML, Lim KP, Peters T, Price J, Takizawa H, Salmon H, Idoyaga J, Ruzo A, Lupo PJ, Hicks MJ, Shih A, Simko SJ, Abhyankar H, et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014.
17. Bubolz AM, Möller P and Lennerz JK. BRAF V600E mutationstatus in histiocytoses does not allow diagnostic distinction between pulmonary and systemic disease. Der Pathologe. 2013; 34(S1):P96-97.
18. Haroche J, Cohen-Aubart F, Emile JF, Arnaud L, Maksud P, Charlotte F, Cluzel P, Drier A, Hervier B, Benameur N, Besnard S, Donadieu J and Amoura Z. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2012; 121(9):1495-1500.
19. Haroche J, Charlotte F, Arnaud L, von Deimling A, Helias-Rodzewicz Z, Hervier B, Cohen-Aubart F, Launay D, Lesot A, Mokhtari K, Canioni D, Galmiche L, Rose C, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012; 120(13):2700-2703.
20. O'Malley DP, Kim YS, Vergilio JA, Chen ZW and Weiss LM. BRAF V600E Mutation Specific Immunohistochemistry Is a Rare Finding in Dendritic Cell-and Histiocyte-Derived Tumors Mod Pathol. 2014; 27(S2):366A.
21. Kansal R, Quintanilla-Martinez L, Datta V, Lopategui J, Garshfield G and Nathwani BN. Identification of the V600D mutation in Exon 15 of the BRAF oncogene in congenital, benign langerhans cell histiocytosis. Genes Chromosomes Cancer. 2012; 52(1):99-106.
22. Kilpatrick SE, Wenger DE, Gilchrist GS, Shives TC, Wollan PC and Unni KK. Langerhans' cell histiocytosis (histiocytosis X) of bone. A clinicopathologic analysis of 263 pediatric and adult cases. Cancer. 1995; 76(12):2471-2484.
23. Blombery P, Wong SQ, Lade S and Prince HM. Erdheim-Chester disease harboring the BRAF V600E mutation. J Clin Oncol. 2012; 30(32):e331-332.
24. Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, Pucciarini A, Bigerna B, Pacini R, Wells VA, Sportoletti P, Pettirossi V, Mannucci R, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011; 364(24):2305-2315.
25. Nelson DS, Quispel W, Badalian-Very G, van Halteren AG, van den Bos C, Bovee JV, Tian SY, Van Hummelen P, Ducar M, Macconaill LE, Egeler RM and Rollins BJ. Somatic activating ARAF mutations in Langerhans cell histiocytosis. Blood. 2014.
26. Sondergaard JN, Nazarian R, Wang Q, Guo D, Hsueh T, Mok S, Sazegar H, MacConaill LE, Barretina JG, Kehoe SM, Attar N, von Euw E, Zuckerman JE, et al. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med. 2010; 8:39.
27. Grabellus F, Worm K, Schmid KW and Sheu SY. The BRAF V600E mutation in papillary thyroid carcinoma is associated with glucose transporter 1 overexpression. Thyroid. 2012; 22(4):377-382.
28. Hall A, Meyle KD, Lange MK, Klima M, SanderhoffM, Dahl C, Abildgaard C, Thorup K, Moghimi SM, Jensen PB, Bartek J, Guldberg P and Christensen C. Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene. Oncotarget. 2013; 4(4):584-599.
29. Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe GC, Frederick DT, Hurley AD, Nellore A, Kung AL, Wargo JA, Song JS, Fisher DE, et al. Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF. Cancer Cell. 2013; 23(3):302-315.
30. Parmenter TJ, Kleinschmidt M, Kinross KM, Bond ST, Li J, Kaadige MR, Rao A, Sheppard KE, Hugo W, Pupo GM, Pearson RB, McGee SL, Long GV, et al. Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis. Cancer Discov. 2014; 4(4):423-433.
31. Sheu JJ, Guan B, Tsai FJ, Hsiao EY, Chen CM, Seruca R, Wang TL and Shih Ie M. Mutant BRAF induces DNA strand breaks, activates DNA damage response pathway, and up-regulates glucose transporter-1 in nontransformed epithelial cells. Am J Pathol. 2012; 180(3):1179-1188.
32. Sharma SV, Fischbach MA, Haber DA and Settleman J. "Oncogenic shock": explaining oncogene addiction through differential signal attenuation. Clin Cancer Res. 2006; 12(14 Pt 2):4392s-4395s.
33. Sharma SV, Bell DW, Settleman J and Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007; 7(3):169-181.
34. Heakal Y, Kester M and Savage S. Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma. Ann Pharmacother. 45(11):1399-1405.
35. Nagel PD, Feld FM, Weissinger SE, Stenzinger A, Moller P and Lennerz JK. Absence of BRAF and KRAS hotspot mutations in primary mediastinal B-cell lymphoma. Leuk Lymphoma. 2014.
36. Lennerz JK, Hurov JB, White LS, Lewandowski KT, Prior JL, Planer GJ, Gereau RWt, Piwnica-Worms D, Schmidt RE and Piwnica-Worms H. Loss of Par-1a/MARK3/C-TAK1 kinase leads to reduced adiposity, resistance to hepatic steatosis, and defective gluconeogenesis. Mol Cell Biol. 2010; 30(21):5043-5056.
37. Alayed K, Patel K, Zuo Z, Verma S, Cason R, Galbincea J, Luthra R, Medeiros L and Yin C. BRAF Mutation Occurs More Frequently in Pulmonary Langerhans Cell Histiocytosis and in Younger Patients. J Mol Diagn. 2013; 15(6):858-859.
38. Arceci RJ, Allen CE, Dunkel I, Jacobsen ED, Whitlock J, Vassallo R, Borrello IM, OliffA, Morris SR, Reedy BAM, Portnoy A, Smith DA, Noble B, et al. Evaluation Of Afuresertib, An Oral Pan-AKT Inhibitor, In Patients With Langerhans Cell Histiocytosis. Blood. 2013; 122:2907.
39. Chilosi M, Facchetti F, Calio A, Zamo A, Brunelli M, Martignoni G, Rossi A, Montagna L, Piccoli P, Dubini A, Tironi A, Tomassetti S, Poletti V, et al. Oncogene-induced senescence distinguishes indolent from aggressive forms of pulmonary and non-pulmonary Langerhans cell histiocytosis. Leuk Lymphoma. 2014.
40. Fu B, Wang Z, Li X, Wang SA and Zuo Z. Detection of BRAF V600E Mutation in Langerhans Cell Histiocytosis Using High-resolution Melting Analysis in Decalcified, Paraffin-embedded Tissue. J Leuk. 2013; 1:101.
41. Halfacre JA, Gale JM and Vasef MA. Analysis of BRAF V600E Mutation in Langerhans Cell Histiocytosis Using Pyrosequencing Technology. J Mol Diagn. 2012; 14(6):660.
42. Peters TL, Price J, George R, Lim PH, Heym KM, Merad M, McClain KL and Allen CE. Frequent BRAF V600E Mutations Are Identified in CD207+ Cells in LCH Lesions, but BRAF Status does not Correlate with Clinical Presentation of Patients or Transcriptional Profiles of CD207+ Cells. ASH Meeting 2011. 2011; Poster 602.
43. Roden AC, Hu X, Kip S, Parrilla Castellar ER, Rumilla KM, Vrana JA, Vassallo R, Ryu JH and Yi ES. BRAF V600E Expression in Langerhans Cell Histiocytosis: Clinical and Immunohistochemical Study on 25 Pulmonary and 54 Extrapulmonary Cases. Am J Surg Pathol. 2014; 38(4):548-551.
44. Romano RC, Shon W and Fritche KL. BRAF V600E Immunohistochemistry in Cutaneous Langerhans Cell Histiocytosis. Mod Pathol. 2014; 27(S2):142A.
45. Sahm F, Capper D, Preusser M, Meyer J, Stenzinger A, Lasitschka F, BerghoffAS, Habel A, Schneider M, Kulozik A, Anagnostopoulos I, Mullauer L, Mechtersheimer G, et al. BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood. 2012; 120(12):e28-34.
46. Satoh T, Smith A, Sarde A, Lu HC, Mian S, Trouillet C, Mufti G, Emile JF, Fraternali F, Donadieu J and Geissmann F. B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease. PLoS One. 2012; 7(4):e33891.
47. Wei R, Wang Z, Li X, Shu Y and Fu B. Frequent mutation has no effect on tumor invasiveness in patients with Langerhans cell histiocytosis. Biomed Rep. 2014; 1(3):365-368.
48. Yuan J, Caponetti GC, Lytle D and Greiner TC. Detection of BRAF V600E Mutations in Langerhans Cell Histiocytosis by Pyrosequencing. Mod Pathol. 2013; 26(S2):369A.
49. Yousem SA, Dacic S, Nikiforov YE and Nikiforova M. Pulmonary Langerhans cell histiocytosis: profiling of multifocal tumors using next-generation sequencing identifies concordant occurrence of BRAF V600E mutations. Chest. 2013; 143(6):1679-1684.
50. West DS, Dogan A, Quint PS, Tricker-Klar ML, Porcher JC, Ketterling RP, Law ME, McPhail ED, Viswanatha DS, Kurtin PJ, Dao LN, Ritzer RD, Nowakowski GS, et al. Clonally related follicular lymphomas and Langerhans cell neoplasms: expanding the spectrum of transdifferentiation. Am J Surg Pathol. 2013; 37(7):978-986.
51. Bates SV, Lakshmanan A, Green AL, Terry J, Badalian-Very G, Rollins BJ, Fleck P, Aslam M and Degar BA. BRAF V600E-Positive Multisite Langerhans Cell Histiocytosis in a Preterm Neonate. AJP Rep. 2013; 3(2):63-66.
52. Ducassou S, Seyrig F, Thomas C, Lambilliotte A, Marec-Berard P, Berger C, Plat G, Brugiere L, Ouache M, Barkaoui M, Armari-Alla C, Lutz P, Leverger G, et al. Thymus and mediastinal node involvement in childhood Langerhans cell histiocytosis: long-term follow-up from the French national cohort. Pediatr Blood Cancer. 2013; 60(11):1759-1765.
53. Kamionek M, Welch M, Tomaszewicz K, Hutchinson L, Cosar EF, Dresser K and Fraire AE. BRAF Mutation Analysis in Pulmonary Langerhans Cell Histiocytosis. Mod Pathol. 2012; 25(101):479A.
54. Milne P, Bigley V, McGovern N and Collin M. Revisiting the origin of Langerhans cell histiocytosis: mutated BRAF gene identifies potential circulating precursor cells. Abstract booklet, 13th International workshop on Langerhans Cells. 2013; October 10-13, 2013:13.
55. Mitchell JM, Terrano D, Lee J, Alobeid B, Bhagat G, Mansukhani M and Remotti H. BRAF V600E Mutation in Langerhans Cell Histiocytosis of the Liver. Arch Pathol Lab Med. 2012; 136:1024.
56. Sun F, Sun X, Zhen Z and Zhu J. Case report: Response to BRAF V600E Inhibitor Vemurafenib and Adoptive Immunotherapy in a Patient with Multisystemic and Refractory Langerhans Cell Histiocytosis. Pediatr Blood Cancer. 2013; 60(S3):P152.
57. Yoon JH, Park HJ, Park SY and Park BK. Langerhans cell histiocytosis in non-twin siblings. Pediatr Int. 2013; 55(3):e73-76.
58. Oishi N, Kondo T, Mochizuki K, Inoue T, Kasai K, Nakazawa T, Mitsumori T and Katoh R. Localized Langerhans cell histiocytosis of the thymus with BRAF V600E mutation: a case report with immunohistochemical and genetic analyses. Hum Pathol. 2014; ePub ahead of print.